Melbourne Australia:  Starpharma Holdings Limited (ASX: SPL, OTCQX SPHRY) will be hosting investor conference calls to discuss results of the Company’s phase 3 clinical trial for the treatment of bacterial vaginosis.  The calls will be hosted by Starpharma Chief Executive Officer Dr Jackie Fairley.

To accommodate Starpharma’s international investor base the Company will be holding two conference calls:
Conference call 1 (European and Asian investors): Wednesday 28^th November at 8.30pm EDT (United Kingdom 9.30am Wednesday 28^th November; Singapore/Hong Kong 5.30pm Wednesday 28^th November).  Conference ID 75319844 - This will need to be quoted when joining the call.

Conference call 2 (Australian and US investors): Thursday 29^th November at 9.15am EDT (United States 5.15pm EST / 2.15pm PST).  Conference ID 75320192 - This will need to be quoted when joining the call.

 Dial in details:

 Australian Participant Dial-In Numbers 

02 8314 8370 or Toll-free: 1800 123 296

International Participant Dial In Numbers

These numbers are toll-free dial in numbers for each country listed below. For countries not listed below, the Australian Toll number (+61 2 8314 8370) can be dialed.

China                           4001203085

Hong Kong                  800 908 865

India                            180030106141

Japan                          0120 985 190

New Zealand               0800 452 782

Singapore                    800 616 2288

United Kingdom          0808 234 0757

United States              1855 293 1544

Download ASX Announcement: VivaGel Phase 3 study results investor calls ( pdf file, 80kb)